Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 2007

View Archived Issues

New compounds for treating inflammatory disorders reported in recent patents

Resin increases production of NPI-0052 during fermentation of Salinispora tropica

DNA tuberculosis vaccine shows promise in cynomolgus monkey model

GSK's adjuvanted H5N1 influenza vaccine shows favorable immunogenicity and cross-reactivity

Preclinical characterization of the topical TrkA inhibitor CT-327 for the treatment of psoriasis

CXCR4 antagonist AMD-3465 prevents injury-induced neointimal formation in mice

Lundbeck and Takeda to codevelop and comarket new therapies for psychiatric disorders

Patient recruitment complete for tesamorelin confirmatory phase III trial

Lpath demonstrates preclinical efficacy of Lpathomab and begins humanization process

Dyax and Bayer Schering Pharma enter collaboration for therapeutic antibody R&D

Aradigm and Lung Rx to codevelop inhaled treprostinil using AERx Essence technology

Positive results for Next Pharmaceuticals' study of Relora

PhytoMedical reports preliminary results of preclinical diabetes trial

Cell Therapeutics to conduct full analysis of EXTEND trial after discussions with FDA

NanoViricides reports on novel class of drug candidates for influenza

Medarex and Centocor expand antibody development agreement

FDA grants fast track designation to Poniard's picoplatin for SCLC

Mircera reaches first market for CKD-associated anemia

FDA responds to Encysive's request for formal dispute resolution of Thelin NDA

Accelerated approval of Merck & Co.'s Isentress recommended by FDA Advisory Committee

Pfizer launches 5-year initiative for malaria treatment and education in three countries

Biopure and FDA discuss compassionate use protocol for Hemopure

Innocoll to sell proprietary gentamicin and bupivacaine products to EUSA Pharma

BioDelivery and Meda enter North American BEMA Fentanyl license agreement

LifeCycle begins phase I head-to-head trial of LCP-Tacro vs. Advagraf

Positive results for extension of Akela Pharma's phase IIb Fentanyl Taifun trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...